Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. But the streak didn't last long.

Last week, Gilead announced second-quarter results that were below analysts' expectations. Its revenue declined 10.5% year over year, with adjusted earnings plunging 36%. But is Gilead stock now a buy after its disappointing Q2 results?

Image source: Getty Images.

Continue reading

Source Fool.com